Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:

CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitisConsiderations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistance

Presenters:

BJ Rimel, MD
Division Chief, Gynecologic Oncology
Professor, Department of OB/GYN
University of Washington
Clinical Director of Gynecologic Oncology
Fred Hutchinson Cancer Center
Seattle, Washington

Elizabeth Lee, MD
Division of Gynecologic Oncology
Center for Cancer Therapeutic Innovation
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to full program: 
https://bit.ly/3SqCAZ6

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.